
	Where results make sense

Topic: MeNZB

Related Topics

Vaccine

Meningitis

In the News (Thu 21 Aug 08)

Gordon Brown

Derby County

Mike Huckabee

Lute Olson

Pearl Harbor

Sonia Gandhi

Ricky Hatton

Narendra Modi

Jesus Christ

Rudy Giuliani

	MeNZB - Wikipedia, the free encyclopedia
		MeNZB is a vaccine against a specific strain of group B meningococcus, currently being used to control an epidemic of meningococcal disease in New Zealand.
		There are no live meningococcal bacteria in the vaccine and it is not possible to catch the disease or become a carrier of the disease from the vaccine.
		The antigen in MeNZB is prepared from B:4:P1.7b,4 (NZ 98/254) N. meningitidis strain, grown in a fermentor.
	en.wikipedia.org /wiki/MeNZB (487 words)

	Meningococcal Vaccine Strategy - About Meningococcal Disease (Site not responding. Last check: 2007-11-03)
		A new vaccine called MeNZB™ has been developed to help protect children and young people in New Zealand against the strain of meningococcal B disease that is causing an epidemic in this country.
		There are no live meningococcal bacteria in MeNZB™ vaccine and it is not possible to catch the disease, or to become a carrier of the disease, from the vaccine.
		MeNZB™ vaccine has been developed to protect against the strain of meningococcal B causing the New Zealand epidemic.
	www.immunise.moh.govt.nz /MeNZB.html (1462 words)

	Data Sheet
		MeNZB is indicated for primary immunisation against group B meningococci with the P1.7-b,4* PorA protein ("New Zealand strain").
		The population at risk should be vaccinated with MeNZB to prevent serious systemic disease (septicaemia and meningitis) caused by New Zealand strain serogroup B meningococci.
		MeNZB is presented as a 0.5 ml suspension for injection in a colourless single dose Type I glass vial closed with bromobutyl rubber stoppers.
	www.medsafe.govt.nz /profs/datasheet/m/menzbvac.htm (1744 words)

	Proceedings of the Meningococcal Vaccine Strategy World Health Organization Satellite Meeting, 10 March 2004, Auckland, ...
		MeNZB™ is given by intramuscular injection with the course of immunisations comprising three doses given at 6-week intervals.
		Phase I and Phase II clinical trials of MeNZB™ vaccine are being led by the University of Auckland, under contract to the Ministry of Health.
		MeNZB™ is being given with the routine childhood immunisation schedule to assess immunogenicity and safety in that age group, and interference with the immune response to routine childhood immunisations (DTaP-IPV and Hib-HepB at 6 weeks and 3 months, and DTaP-IPV and HepB at 5 months).
	www.nzma.org.nz /journal/117-1200/1026 (4495 words)

	Consumer Medicine Information
		MeNZB may help to protect you /your child from meningococcal disease but it may have unwanted side effects in a few people.
		MeNZB must be stored in a refrigerator (+2 to +8°Celsius) and must not be frozen.
		MeNZB must also be protected from light (by keeping it in the original pack until it is time for it to be given).
	www.medsafe.govt.nz /consumers/cmi/m/menzb.htm (1388 words)

	New Page 6
		Therefore it cannot be assumed that MeNZB will protect against meningococcal diseases caused by any of the other types of meningococcal bacteria (A, C, 29-E, H, I, K, L, W-135, X, Y, or Z, including non-typeable).
		A vaccination schedule of 3 doses MeNZB given with an interval of 6 weeks between doses induces a humoral immune response against the New Zealand strain.
		Data from trials using a vaccination schedule of 3 doses MeNZB given with an interval of 6 weeks demonstrate that 74% infants, 75% toddlers, 74% children, and 91% adults developed a 4-fold rise (compared with pre-vaccination values) in serum bactericidal antibody titres 4-6 weeks after the third dose.
	poisonevercure.150m.com /vaccines/package_inserts/menzb.htm (1567 words)

	:::► Dictionary of Meaning www.mauspfeil.net ◄:::
		'''MeNZB''' is a vaccine against a specific strain of group B meningococcus, currently being used to control an epidemic of meningitis in New Zealand.
		Each dose is 0.5 ml and contains: 25 mcg of outer membrane vesicles from the ''Neisseria meningitidis'' group B strain NZ98/245 1.65 mg of aluminium hydroxide (an adjuvant) histidine (to stabilise the pH) normal saline (medicine) saline The vaccine does not contain any whole bacteria (alive or dead).
		MeNZB vaccine does not contain any human, blood, or bovine products, egg (food) egg products, neomycin or the preservative thiomersal.
	www.mauspfeil.net /MeNZB.html (448 words)

	Immunoblogging: MeNZB and Phase III trials
		Firstly, there are in fact several vaccines that are similar to MeNZB being used at the moment, including the 'parent' vaccine that MeNZB was based on that was developed in Norway.
		The only considerable difference between the Norweigan vaccine and MeNZB is the antigen (the bit the immune system responds to in the vaccine) is different: the two vaccines were produced in the same way.
		Conceptually, there is little difference between the concept behind the MeNZB vaccine and changing the antigens in the influenza vaccine every year except that certain groups complain about one and not the other.
	immunoblogging.blogspot.com /2005/08/menzb-and-phase-iii-trials.html (876 words)

	Men B Vaccine (Site not responding. Last check: 2007-11-03)
		The MeNZB™ vaccine was approved under a loop-hole in the Medicines Act that allows for restricted use of experimental drugs in a limited number of patients.
		Our evidence indicates that the first batch of MeNZB™ vaccine used in the clinical trials was manufactured in Norway by the NIPH at least as early as September 2001, nearly two months before the Cabinet approved funding which included the development of the vaccine.
		In its critique of the MeNZB™ Quick Guide the MOH stated, “The trials showed the vaccine to be safe and effective in generating a protective antibody response.
	www.investigatemagazine.com /_PARENTTALK/00000039.htm (18202 words)

	Scoop: Extra protection for babies with 4th MeNZB dose
		This follows medicines regulator Medsafe granting approval for a 4th dose of the vaccine to be administered to babies, the age group at greatest risk from the country's group B meningococcal epidemic.
		Additional data, from extension studies, on the administration of a 4th MeNZB vaccine showed a clear increase in response rate (four-fold rise) as would be expected with a primary course that consists of four doses in the first year of life.
		The 4th MeNZB dose should be given to babies at least 10 months old, and a minimum of four months after their 3rd dose.
	www.scoop.co.nz /stories/GE0601/S00019.htm (2071 words)

	News (Site not responding. Last check: 2007-11-03)
		For those children/youth who have not started or completed their MeNZB™ vaccinations, it is still available and will be given through GP practices and a Meningococcal B Outreach Immunisation Service.
		The mass immunisation campaign ends on 30 June 2006 and it is important that everyone under the age of 20 completes all 3 doses of the MeNZB™ vaccine before 30 June 2006.
		For more information on the MeNZB™ campaign please phone your own Doctor or the Otago Meningococcal B team on 0800 23 32 44.
	www.correspondence.school.nz /news/news_article.php?seqid=771 (214 words)

	National Women's Newborn Services Clinical Guideline - Meningococcal B (MeNZB) Vaccination
		MOH guidelines indicate that the MeNZB vaccination can be given at the same time but at a site 2.5cm away from the other vaccination site.
		All infants who receive the MeNZB vaccination must be recorded on the vaccination register monitored by the Ministry of Health.
		They are unable to opt out of the register of MeNZB vaccinations if they choose to have the meningococcal vaccination, so the choice is either vaccinate and register, or no vaccination.
	www.adhb.govt.nz /newborn/Guidelines/Infection/Immunisation/MeNZB.htm (297 words)

	MeNZB VACCINATION CAMPAIGN :: Salient
		MeNZB vaccinations are only available for those that are under the age of 20 years on the date of their first vaccination.
		It is available and free for International students under the age of 20 years providing they will be in the country long enough to complete the course.
		If the students will be turning 20 during May and will not be seen at one of the campaign sites before their birthday they should go to Student Health Kelburn for their immunisation prior to their birthday.
	www.salient.org.nz /index.php?a=1433&c=57 (455 words)

	UNCENSORED » THE MeNZB CAMPAIGN OF FEAR – A $200m SCANDAL (Site not responding. Last check: 2007-11-03)
		In a public meeting she stated that the MeNZB™ vaccine was expected to be more effective because Kiwi kids will be receiving 3 doses of the vaccine.
		However, even if the MeNZB™ vaccine does prove to be effective in preventing meningococcal disease caused by the target strain of meningococcal bacteria, the new vaccine is not expected to prevent all cases of meningococcal disease.
		The case of the MeNZB™ vaccine which is being used in a mass vaccination campaign even though it couldn’t even gain full registration is a perfect illustration of this.
	uncensored.co.nz /archives/2005/09/01/the-menzb-campaign-of-fear-a-200m-scandal (9600 words)

	The Meningococcal Gold Rush by Barbara Sumner Burstyn
		The documents also show that when Chiron finally manufactured and tested its MeNZB vaccine in its Italian factory, it was so late in the trial process that the Minister’s MAAC Vaccine Sub-Committee notes that no results of either of the tests were completed when they recommended the vaccine be approved for general release.
		A university source has revealed that the paper was removed to protect the interests of the student after the University received a threatening letter ‘advising against publication.’ We are aware of the student’s name and have been asked not to make it public as to do so could jeopardize their career options.
		The only grounds for raising the prospect of herd immunity by the officials would appear to be to amplify the potential benefits of the meningococcal vaccine in an attempt to convince Cabinet that Treasury had been too conservative in their assessments.
	www.whale.to /vaccine/investigation.html (5244 words)

	Scoop: The Meningococcal Gold Rush - Second Edition (Site not responding. Last check: 2007-11-03)
		At the same time, in their scientific publication, the MeNZB authors, who include the MOH spokesperson, state; “these findings suggest that MeNZB is safe and is likely to confer protection” The use of the terms “suggest” and “likely” used in their scientific writings
		This being the case, then the expectation of the researchers and the Ministry of Health is that the MeNZB vaccine will reduce the incidence of meningococcal disease in New Zealand by only 37 percent.
		The MOH funded studies show that carriage of meningococcal bacteria in about 20 percent of the population at any one time is not affected by the MeNZB vaccine and therefore herd protection is most unlikely.
	img.scoop.co.nz /stories/HL0505/S00352.htm (18709 words)

	Immunoblogging: MeNZB
		Countering the poor public relations our smallest and most essential partners in life suffer from the anti-microbe media.
		It appears that the MeNZB vaccine is having an effect with the number of Meningococcal cases having dropped significantly this year compared with last year;
		The current total number of notified cases for 2005 so far is 151 with nine deaths.
	immunoblogging.blogspot.com /2005/08/menzb.html (262 words)

	The MeNZB vaccine will work (Site not responding. Last check: 2007-11-03)
		The New Zealand Ministry of Health followed an internationally accepted process for licensing the MeNZB vaccine.
		Director-General of Health Dr Karen Poutasi said today that the MeNZB vaccine, used in the Meningococcal B Immunisation Programme, has gone through the clinical trials required for such a vaccine.
		The MeNZB vaccine is protective against the epidemic strain of meningococcal disease.
	www.news-medical.net /?id=10858 (580 words)

	MeNZB: Facts and details from Encyclopedia Topic (Site not responding. Last check: 2007-11-03)
		MeNZB is a vaccine (Immunogen consisting of a suspension of weakened or dead pathogenic cells injected in order to stimulate the production of antibodies)
		MeNZB vaccine does not contain any human, Exception Handler: No article summary found.
		The antigen in MeNZB is prepared from B:4:P1.7b,4 (NZ 98/254) N, Exception Handler: No article summary found.
	www.absoluteastronomy.com /ref/menzb3 (688 words)

	The Meningococcal Gold Rush
		This is especially pertinent given that on the same day MedSafe extended by 18 months [30] the about-to-expire use-by date of over 300,000 doses of the vaccine that had been produced in commercial quantities by Chiron, months in advance of the completion of trials and licensing.
		The infants were given Menjugate™ vaccine as a so-called ‘placebo.’ [18] This fact is not mentioned in the MAAC minutes but was disclosed in a paper presented by Chiron at a scientific conference in Japan in October 2004.
		While Chiron’s withdrawn Menjugate™ made it to Phase III trials [48] the New Zealand Minister vetoed the idea of Phase III trials for MeNZB™ saying it was agreed that the amount of safety and efficacy information on the Norwegian specific vaccine produced in Norway for Norway could be bridged to the New Zealand clinical trials.
	www.endohealth.co.nz /iavmengd.htm (5301 words)

	Webhealth Taranaki \| Be Wise, Immunise
		The MeNZB™ vaccine is available to everyone in New Zealand aged from six weeks to 19 years.
		There are no live bacteria in the vaccine, so it cannot cause meningococcal disease and it cannot lower your immunity to other infections.
		The MeNZB™ vaccine is the best protection available against the epidemic strain of meningococcal disease in New Zealand.
	taranaki.webhealth.co.nz /hyperlink/bewiseimmunise.php (563 words)

	Meningococcal B Vaccine Campaign in NZ
		There is no contention among scientists or doctors about the safety and effectiveness of the MeNZB meningococcal vaccine."Â Her statement is of course at variance with the hard facts.
		For example,Â the pre-licensing trials of the Measles-Mumps-Rubella triple live vaccine (MMR) conducted in the UK in the late 1980s involved much longer observation periods of up to a month.Â Even so in "The Journal of Adverse Reactions" (Jan. 2001) a number of senior UK clinicians were critical of those safety tests.Â Dr. A.
		You must bear in mind that up to 45% of the population at any one timeÂ have a strain or strains of meningococcal bacteria in their tonsular tissue, as studies of removed tonsils have revealed.
	www.cleangreencar.co.nz /show_article/3d_views.html (2891 words)

	CriticWeb::Archive - This won’t hurt a bit: MeNZB shots get underway (Site not responding. Last check: 2007-11-03)
		Today marks the start of a major campaign to immunise those Dunedin students who are under 20 against some strains of meningitis.
		The campaign will be officially launched on Wednesday in the Union, in order to inform students about the MeNZB vaccine.
		The vaccine is being offered free of charge to those under 20 as part of a government-funded scheme to help protect young people against the B strain of the meningococcal disease.
	www.critic.co.nz /showfeature.php?id=2999 (351 words)

	Apria - resources - News (Site not responding. Last check: 2007-11-03)
		Health Minister Annette King at the weekend rejected claims that the late delivery of the influenza vaccine will affect the MeNZB campaign, because two age groups are involved.
		The MeNZB campaign targets young people aged six months up to 20 years, whereas the elderly and chronically ill are the main groups vaccinated against influenza.
		Ms Corke said there has been a promising response to calls to recruit more nurse vaccinators to support the MeNZB programme, and the board is working to ensure health centres have capacity to cope with the dual workload.
	www.apria.com /resources/1,2725,494-292454,00.html (651 words)

	WELCOME TO THE GE FREE NEW ZEALAND WEBSITE (Site not responding. Last check: 2007-11-03)
		The parent vaccine came from the Norwegian meningococcal group B strain.
		MeNZB will not protect against meningococcal diseases caused by any of the other types of meningococcal bacteria A, C, 29-E, H, I, K, L, W-135, X, Y, or Z, including non-typeable) or serogroup B other than the New Zealand strain.
		Administration of MeNZB should usually be postponed in persons with an acute febrile illness (fever > 38.5 °C).
	www.gefree.org.nz /meninginfo.htm (603 words)

Try your search on: Qwika (all wikis)